FDA Class II Recall: Turbare Manufacturing's Avastin Repackaging Fails Sterility Assurance
Turbare Manufacturing initiated a Class II recall for 1,147 syringes of repackaged Avastin 1.25 mg/0.05 mL due to a critical lack of sterility assurance from a quality control process deviation. This event underscores significant supply chain and regulatory risks for procurement and regulatory affairs teams sourcing sterile injectable products, demanding immediate review of supplier qualification protocols.
FDA Class II Recall: Turbare Manufacturing's Avastin Sterility Failure
On February 18, 2025, Turbare Manufacturing, based in Conway, Arkansas, initiated a voluntary Class II recall for 1,147 syringes of repackaged Avastin 1.25 mg/0.05 mL in 0.25 mL syringes (NDC: 83556-0101-01). This critical action, designated recall number D-0248-2025, was prompted by a severe lack of assurance of sterility, directly attributed to a deviation in the company’s quality control process. For procurement directors and supply chain VPs, this event highlights an immediate and high-risk vulnerability within the sterile drug supply chain. The product, intended for intravitreal injection and marked for office use only, was distributed nationwide across the USA, meaning any healthcare provider or clinic utilizing this specific repackaged Avastin lot faces potential patient safety risks and operational disruption. The affected lots, 12122024@2 (with a Beyond Use Date of March 12, 2025) and 12192024@2 (BUD of April 18, 2025), underscore the time-sensitive nature of such sterility issues. Business development executives must recognize that such fundamental quality failures can severely damage market trust and necessitate rapid, transparent communication with downstream partners to preserve commercial relationships and mitigate liability.
Operational Impact and Supply Chain Considerations for Repackaged Avastin
Turbare Manufacturing, operating from 925 Jeanette Drive, Conway, AR 72032-6651, functions as a repackager of critical pharmaceutical products like Avastin. The recall of 1,147 syringes of Avastin, a biologic used for ophthalmic conditions, due to sterility issues, has direct and immediate implications for the supply chain. Procurement teams must ascertain if their organizations have sourced these specific lots (12122024@2, 12192024@2) of repackaged Avastin (NDC: 83556-0101-01) from Turbare Manufacturing. Given the product's 'Office Use Only - Not for Resale' designation, distribution typically targets clinics, hospitals, and specialized ophthalmology practices directly. The nationwide distribution pattern in the USA means the impact is geographically broad, requiring a comprehensive internal audit of inventory and usage records. For regulatory affairs heads, this incident necessitates a review of supplier qualification processes for all third-party repackagers, particularly those handling sterile injectable drugs. The 'quality control process deviation' points to systemic issues that could affect other products from this facility, demanding heightened due diligence. Supply chain VPs should evaluate the robustness of their contingency plans for critical sterile products, as reliance on a single repackager, especially one experiencing such a fundamental quality failure, poses unacceptable continuity risks.
Heightened Regulatory Scrutiny on Sterile Drug Quality Assurance
The FDA's classification of this as a Class II recall for a lack of sterility assurance signals significant patient risk, as contaminated injectable products can lead to severe infections or life-threatening adverse events. This incident with Turbare Manufacturing aligns with a broader trend of increased FDA scrutiny on sterility and quality control within the pharmaceutical industry. For instance, recent parallel events include the FDA's Class II recall of Essential Wellness Pharma's Progesterone Injection due to similar sterility assurance failures, published in June 2026. While not directly linked to Turbare, such events underscore the FDA's unwavering focus on robust quality management systems (QMS) for sterile products. Regulatory affairs heads must interpret this as a clear signal that the FDA expects impeccable adherence to current Good Manufacturing Practices (cGMP), particularly regarding aseptic processing and environmental controls. A 'quality control process deviation' is not merely an operational hiccup; it indicates a failure in foundational QMS elements, which can prompt further FDA inspections and potential enforcement actions beyond the recall itself. Business development executives should note that consistent quality failures can lead to market exclusion and significant reputational damage, impacting long-term commercial viability in a highly regulated sector.
Navigating Remediation and Long-Term Compliance for Sterile Product Manufacturers
Turbare Manufacturing's recall was initiated on February 18, 2025, classified by the FDA on February 21, 2025, and officially terminated on February 26, 2026. While the 'Completed' status indicates that the firm has concluded its recall activities and removed the product from distribution, it does not signify an end to regulatory scrutiny. For regulatory affairs heads, this termination date marks a critical point for evaluating Turbare's subsequent actions. The underlying 'quality control process deviation' that led to the sterility issue demands comprehensive corrective and preventive actions (CAPA). The FDA will expect a thorough investigation into the root cause, implementation of robust controls, and verification of their effectiveness. Failure to adequately address these issues could lead to future FDA Form 483 observations during subsequent inspections, or even a Warning Letter, impacting Turbare's ability to supply sterile products. Procurement directors and supply chain VPs should consider this recall a significant risk indicator, necessitating ongoing monitoring of Turbare Manufacturing's compliance status and potentially diversifying their supplier base for critical sterile injectables like Avastin to mitigate future supply disruptions and ensure patient safety.